Telegram Messenger Support for Smoking Cessation After Heart Attack
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorITMO University
About this trial
This randomized controlled trial will evaluate whether a 6-month behavioral intervention delivered via Telegram messenger increases smoking cessation rates in patients after myocardial infarction (MI).
Adult smokers hospitalized with acute MI who regularly use Telegram will be randomly assigned to either:
* INTERVENTION GROUP: Standard care plus a 6-month Telegram chatbot program providing personalized motivational messages, cognitive-behavioral techniques for craving management, and relapse prevention support. * CONTROL GROUP: Standard care (routine physician advice to quit smoking) plus basic surveys via Telegram without therapeutic content.
The primary outcome is 30-day point prevalence abstinence at 6 months, verified by blinded telephone interview with participant and corroborating report from a close relative. Secondary outcomes include changes in cigarette consumption, nicotine dependence, motivation, and intervention engagement metrics.
This study addresses the critical gap in smoking cessation support after hospital discharge and could provide evidence for a scalable digital health solution in cardiac secondary prevention.
Eligibility criteria
Qualifiers
Willing and able to provide written informed consent.
Age 18 years or older.
Hospitalization with a confirmed diagnosis of acute myocardial infarction (MI), including both ST-elevation MI (STEMI) and non-ST-elevation MI (NSTEMI).
Current smoker at the time of index MI: self-reported smoking of at least one cigarette per day in the month prior to hospitalization.
Disqualifiers
Smoking cessation more than 1 month prior to the index MI hospitalization.
Physical or cognitive impairment that prevents the use of a smartphone (e.g., severe visual/hearing impairment, inability to read or respond to messages).
Inability to read and understand the Russian language fluently.
Comorbid condition with a life expectancy of less than 1 year.
Trial design
Treatments tested in this trial
- Telegram-based Smoking Cessation Support
- Standard Care (in control arm)
Treatment groups
142 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov